Chronic hepatitis B: Update of recommendations
- 1 March 2004
- journal article
- guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 39 (3), 857-861
- https://doi.org/10.1002/hep.20110
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis BJournal of Hepatology, 2003
- Durability of serologic response after lamivudine treatment of chronic hepatitis BHepatology, 2003
- Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferaseGut, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis BThe New England Journal of Medicine, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis BThe New England Journal of Medicine, 2003
- Histological outcome during long-term lamivudine therapyGastroenterology, 2003
- Clinical Trial of Lamivudine in Children with Chronic Hepatitis BThe New England Journal of Medicine, 2002
- Effect of virological response on post‐treatment durability of lamivudine‐induced HBeAg seroconversionJournal of Viral Hepatitis, 2002
- Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B?Journal of Hepatology, 2002
- Chronic hepatitis BHepatology, 2001